风投组合、上游企业协作与关键核心技术突破——基于高端医疗设备行业的实证研究  

Venture Capital Portfolio,Upstream Enterprise Collaboration and Key Core Technology Breakthrough——Empirical Research Based on Advanced Medical Device Industry

作　　者：冯婷 郭立宏[1] 董建卫[1] FENG Ting;GUO Li-hong;DONG Jian-wei(School of Economics and Management,Northwestern University,Xi'an 710127,China)

机构地区：[1]西北大学经济管理学院,陕西西安710127

出　　处：《山西财经大学学报》2023年第1期85-98,共14页Journal of Shanxi University of Finance and Economics

基　　金：国家自然科学基金地区项目(71962033);国家自然科学基金青年项目(72102173);陕西省社会科学基金项目(2021R029)。

摘　　要：从解决高端医疗设备企业上游协作困境的现实需要入手,以2015—2021年有风险投资(VC)背景的高端医疗设备企业为样本,利用中国高端医疗设备批准注册信息和专利数据,构造高端医疗设备企业关键核心技术突破数据集,探讨了VC机构帮助企业突破关键核心技术的路径。研究结果表明:VC机构通过构造包含高端医疗设备行业上游企业的投资组合,能有效帮助企业突破关键核心技术,具体表现为帮助企业开发具有国产替代性质的新产品和新技术;地理邻近性、VC机构联合投资均能强化包含上游企业的VC投资组合与企业关键核心技术突破之间的关系。Starting from the practical need to solve the upstream collaboration dilemma of advanced medical device enterprises,this paper took the advanced medical device enterprises with venture capital(VC)investment background from 2015 to 2021 as a sample,and used the approval registration information and patent data to construct the data set of key core technology breakthrough.At last,we explored the ways for VC institutions to help enterprises realize key core technology breakthrough.The results showed that,VC institutions could effectively help enterprises make key core technology breakthrough by constructing the investment portfolio containing upstream enterprises in advanced medical device industry.Specifically,VC institutions could help enterprises develop new products and technologies with domestic substitution nature.Both geographic proximity and VC syndicate could strengthen the aforementioned relationship.

关 键 词：关键核心技术 风险投资组合 高端医疗设备 上游企业协作 国产替代 

分 类 号：F832.48[经济管理—金融学]